Cresilon snagged its second FDA clearance for human use. The FDA granted 510(k) clearance to Traumagel, the startup’s gel that can stop bleeding in just seconds, for temporary external use to control moderate to severe bleeding.
Cresilon, a startup that makes a hemostatic gel to stop bleeding, has raised $25 million in a Series A-4 financing round. The round brings the company's total funding to date to nearly $82 million. The funds will help support Cresilon's entrance into the human health market, as its gel is currently used only by veterinarians.
Radiologists today face a surge in imaging volume and pressure to produce fast, accurate reports. Workflow optimization is about delivering the right results at the right time with less friction.